Last updated date
ABOUT THIS STUDY
The study hypothesis is that the Xal-Ease with increase patient compliance with XALATAN
Study Location
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
706-721-1150
Eligibility Criteria
condition
Glaucoma
Sex
Females and Males
Age
40-80 years
Inclusion Criteria
Show details
- 40 to 80 years old
- Diagnosis warranting treatment with Xalatan eye drops.
- ambulatory and well functioning
Exclusion Criteria
Show details
- non-ambulatory
- less than 40 or greater than 80 years old
- Not using Xalatan eye drops
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
GlaucomaComparison of Visual Fields: Humphrey Field Analyzer (HFA) SITA Strategy, SCOPE (GATE Strategy) and Humphrey MATRIX Perimeter
NCT01068938
- Tuebingen,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
GlaucomaEffect of Age on Latanoprost 0.005% in Patients With Glaucoma
NCT00224289
- New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
GlaucomaDoes Lowering Eye Pressure Affect the Results Obtained From Objective Visual Field Testing?
NCT00799994
- Philadelphia, Pennsylvania
ALL GENDERS
0+
years
MULTIPLE SITES
GlaucomaHow Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?
NCT00798694
- Philadelphia, Pennsylvania
ALL GENDERS
21 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Effects of Xal-Ease on Patient Compliance With Xalatan | |||
Official Title ICMJE | The Effects of the Xal-Ease Delivery Aid Device on Patient Compliance With Xalatan Eye Drops | |||
Brief Summary | The study hypothesis is that the Xal-Ease with increase patient compliance with XALATAN | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Not Applicable | |||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Glaucoma | |||
Intervention ICMJE | Device: Xal-Ease device to be used with Xalatan eye drops
This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop. | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Unknown status | |||
Estimated Enrollment ICMJE | 50 | |||
Original Estimated Enrollment ICMJE | Same as current | |||
Estimated Study Completion Date ICMJE | December 2009 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 40 Years to 80 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00573638 | |||
Other Study ID Numbers ICMJE | 05-02-266 Guarantor or CPI # 002533552 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Michelle Christiano, Medical College of Georgia | |||
Study Sponsor ICMJE | Augusta University | |||
Collaborators ICMJE | Pfizer | |||
Investigators ICMJE |
| |||
PRS Account | Augusta University | |||
Verification Date | August 2008 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |